Role of serum complement C3 and C4 on kidney outcomes in IgA nephropathy.
C3
C4
Complement
Glomerulonephritis
IgA nephropathy
MEST
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
13 Jul 2024
13 Jul 2024
Historique:
received:
29
04
2024
accepted:
25
06
2024
medline:
14
7
2024
pubmed:
14
7
2024
entrez:
13
7
2024
Statut:
epublish
Résumé
IgA Nephropathy (IgAN) is the most prevalent glomerular disease worldwide. Complement system activation is crucial in its pathogenesis. Few studies correlated serum C3 and C4 with disease activity and prognosis. This retrospective study investigated the prognostic value of serum complement at the time of diagnosis in patients with IgAN. Specifically we evaluated whether adding serum C3 and C4 levels to established predictive models-one based on variables related to chronic kidney disease (CKD) progression and another incorporating variables from the International IgA Prediction Tool (IntIgAPT)-enhances the accuracy of outcome prediction. A composite renal outcome was defined as 50% decline in eGFR or onset of kidney failure. 101 patients were stratified according to baseline C3 levels in three groups (Low, Medium and High). During a median follow-up of 54 months, the Low group exhibited higher incidence of primary outcome (16.3 events vs 2.9 and 1.7 events × 100 pts/year, p = 0.0026). Model-1 (M1), consisting of CKD progression variables, and Model-3 (M3), comprising IntIgANPT variables, were implemented with baseline C3 and C4 to create Model-2 (M2) and Model-4 (M4), respectively. M2 demonstrated better predictive performance over M1, showing higher discrimination (lower AIC and BIC, higher C-index and NR2). Similarly, M4 outperformed M3, showing enhanced outcome prediction when C3 and C4 levels were added. Implementation of serum C3 and C4 can enhance prediction accuracy of already-validated prognostic models in IgAN. Lower C3 and higher C4 levels were associated with poorer prognosis, highlighting a more 'Complement-Pathic' subset of patients.
Identifiants
pubmed: 39003309
doi: 10.1038/s41598-024-65857-w
pii: 10.1038/s41598-024-65857-w
doi:
Substances chimiques
Complement C3
0
Complement C4
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
16224Informations de copyright
© 2024. The Author(s).
Références
O’Shaughnessy, M. M. et al. Glomerular disease frequencies by race, sex and region: Results from the International Kidney Biopsy Survey. Nephrol. Dial Transplant. 33(4), 661–669 (2018).
pubmed: 29106637
doi: 10.1093/ndt/gfx189
Lai, K. N. et al. IgA nephropathy. Nat. Rev. Dis. Primers. 2, 16001 (2016).
pubmed: 27189177
doi: 10.1038/nrdp.2016.1
Rodrigues, J. C., Haas, M. & Reich, H. N. IgA nephropathy. Clin. J. Am. Soc. Nephrol. 12(4), 677–686 (2017).
pubmed: 28159829
pmcid: 5383386
doi: 10.2215/CJN.07420716
Rovin, B. H. et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int. 100(4), 753–779 (2021).
pubmed: 34556300
doi: 10.1016/j.kint.2021.05.015
Bartosik, L. P., Lajoie, G., Sugar, L. & Cattran, D. C. Predicting progression in IgA nephropathy. Am. J. Kidney Dis. 38(4), 728–735 (2001).
pubmed: 11576875
doi: 10.1053/ajkd.2001.27689
Tanaka, S. et al. Development and validation of a prediction rule using the Oxford classification in IgA nephropathy. Clin. J. Am. Soc. Nephrol. 8(12), 2082–2090 (2013).
pubmed: 24178970
pmcid: 3848397
doi: 10.2215/CJN.03480413
Chen, T. et al. Prediction and risk stratification of kidney outcomes in IgA nephropathy. Am. J. Kidney Dis. 74(3), 300–309 (2019).
pubmed: 31031086
doi: 10.1053/j.ajkd.2019.02.016
Barbour, S. J. et al. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med. 179(7), 942–952 (2019).
pubmed: 30980653
pmcid: 6583088
doi: 10.1001/jamainternmed.2019.0600
Provenzano, M. et al. Contribution of predictive and prognostic biomarkers to clinical research on chronic kidney disease. Int. J. Mol. Sci. 21(16), 5846 (2020).
pubmed: 32823966
pmcid: 7461617
doi: 10.3390/ijms21165846
Maillard, N. et al. Current understanding of the role of complement in IgA nephropathy. J. Am. Soc. Nephrol. 26(7), 1503–1512 (2015).
pubmed: 25694468
pmcid: 4483595
doi: 10.1681/ASN.2014101000
Roos, A. et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J. Am. Soc. Nephrol. 17(6), 1724–1734 (2006).
pubmed: 16687629
doi: 10.1681/ASN.2005090923
Seelen, M. A., Roos, A. & Daha, M. R. Role of complement in innate and autoimmunity. J. Nephrol. 18(6), 642–653 (2005).
pubmed: 16358221
Bi, T. D. et al. Serum complement C4 is an important prognostic factor for IgA nephropathy: A retrospective study. BMC Nephrol. 20(1), 244 (2019).
pubmed: 31272400
pmcid: 6610919
doi: 10.1186/s12882-019-1420-0
Pan, M. et al. Increased C4 and decreased C3 levels are associated with a poor prognosis in patients with immunoglobulin A nephropathy: A retrospective study. BMC Nephrol. 18(1), 231 (2017).
pubmed: 28697742
pmcid: 5505039
doi: 10.1186/s12882-017-0658-7
Tangri, N. et al. Multinational assessment of accuracy of equations for predicting risk of kidney failure: A meta-analysis. JAMA 315, 164–174 (2016).
pubmed: 26757465
pmcid: 4752167
doi: 10.1001/jama.2015.18202
Uffing, A. et al. Recurrence of IgA nephropathy after kidney transplantation in adults. Clin. J. Am. Soc. Nephrol. 16(8), 1247–1255 (2021).
pubmed: 34362788
pmcid: 8455056
doi: 10.2215/CJN.00910121
Anders, H. J., Peired, A. J. & Romagnani, P. SGLT2 inhibition requires reconsideration of fundamental paradigms in chronic kidney disease, “diabetic nephropathy”, IgA nephropathy and podocytopathies with FSGS lesions. Nephrol. Dial Transplant. 37(9), 1609–1615 (2022).
pubmed: 33313878
doi: 10.1093/ndt/gfaa329
Wheeler, D. C. et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 100(1), 215–224 (2021).
pubmed: 33878338
doi: 10.1016/j.kint.2021.03.033
Heerspink, H. J. L. et al. Sparsentan in patients with IgA nephropathy: A prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet. 401(10388), 1584–1594 (2023).
pubmed: 37015244
doi: 10.1016/S0140-6736(23)00569-X
Noris, M. & Remuzzi, G. Overview of complement activation and regulation. Semin. Nephrol. 33(6), 479–492 (2013).
pubmed: 24161035
pmcid: 3820029
doi: 10.1016/j.semnephrol.2013.08.001
Roberts, I. S. Pathology of IgA nephropathy. Nat. Rev. Nephrol. 10(8), 445–454 (2014).
pubmed: 24861083
doi: 10.1038/nrneph.2014.92
Wu, D. et al. Mesangial C3 deposition and serum C3 levels predict renal outcome in IgA nephropathy. Clin. Exp. Nephrol. 25(6), 641–651 (2021).
pubmed: 33620604
doi: 10.1007/s10157-021-02034-7
Xie, M. et al. Predictive prognostic value of glomerular C3 deposition in IgA nephropathy. J. Nephrol. 36(2), 495–505 (2023).
pubmed: 35781866
doi: 10.1007/s40620-022-01363-4
Wu, J. et al. Severe glomerular C3 deposition indicates severe renal lesions and a poor prognosis in patients with immunoglobulin A nephropathy. Histopathology. 78(6), 882–895 (2021).
pubmed: 33336446
doi: 10.1111/his.14318
Medjeral-Thomas, N. R. et al. Progressive IgA nephropathy is associated with low circulating Mannan-binding lectin-associated serine protease-3 (MASP-3) and increased glomerular factor H-related protein-5 (FHR5) deposition. Kidney Int. Rep. 3(2), 426–438 (2017).
pubmed: 29725647
pmcid: 5932138
doi: 10.1016/j.ekir.2017.11.015
Espinosa, M. et al. Association of C4d deposition with clinical outcomes in IgA nephropathy. Clin. J. Am. Soc. Nephrol. 9(5), 897–904 (2014).
pubmed: 24578331
pmcid: 4011455
doi: 10.2215/CJN.09710913
Segarra, A. et al. Mesangial C4d deposits in early IgA nephropathy. Clin. J. Am. Soc. Nephrol. 13(2), 258–264 (2018).
pubmed: 29146701
doi: 10.2215/CJN.02530317
Gharavi, A. G. et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat. Genet. 43(4), 321–327 (2011).
pubmed: 21399633
pmcid: 3412515
doi: 10.1038/ng.787
Kiryluk, K. et al. Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet. 8(6), e1002765 (2012).
pubmed: 22737082
pmcid: 3380840
doi: 10.1371/journal.pgen.1002765
Medjeral-Thomas, N. R. et al. Circulating complement factor H-related proteins 1 and 5 correlate with disease activity in IgA nephropathy. Kidney Int. 92(4), 942–952 (2017).
pubmed: 28673452
pmcid: 5611987
doi: 10.1016/j.kint.2017.03.043
Tortajada, A. et al. Elevated factor H-related protein 1 and factor H pathogenic variants decrease complement regulation in IgA nephropathy. Kidney Int. 92(4), 953–963 (2017).
pubmed: 28637589
doi: 10.1016/j.kint.2017.03.041
Le Stang, M. B., Gleeson, P. J., Daha, M. R., Monteiro, R. C. & van Kooten, C. Is complement the main accomplice in IgA nephropathy? From initial observations to potential complement-targeted therapies. Mol. Immunol. 140, 1–11 (2021).
pubmed: 34601376
doi: 10.1016/j.molimm.2021.09.010
Kim, S. J. et al. Decreased circulating C3 levels and mesangial C3 deposition predict renal outcome in patients with IgA nephropathy. PLoS One. 7(7), e40495 (2012).
pubmed: 22792353
pmcid: 3391269
doi: 10.1371/journal.pone.0040495
Wyatt, R. J. et al. Complement activation in IgA nephropathy. Kidney Int. 31(4), 1019–1023 (1987).
pubmed: 3586493
doi: 10.1038/ki.1987.101
Zwirner, J. et al. Activated complement C3: A potentially novel predictor of progressive IgA nephropathy. Kidney Int. 51(4), 1257–1264 (1997).
pubmed: 9083294
doi: 10.1038/ki.1997.171
Tomino, Y. et al. Measurement of serum IgA and C3 may predict the diagnosis of patients with IgA nephropathy prior to renal biopsy. J. Clin. Lab. Anal. 14(5), 220–223 (2000).
pubmed: 11018800
pmcid: 6808025
doi: 10.1002/1098-2825(2000)14:5<220::AID-JCLA4>3.0.CO;2-2
Maeda, A. et al. Significance of serum IgA levels and serum IgA/C3 ratio in diagnostic analysis of patients with IgA nephropathy. J. Clin. Lab. Anal. 17(3), 73–76 (2003).
pubmed: 12696075
pmcid: 6808150
doi: 10.1002/jcla.10071
Yanagawa, H. et al. A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases. PLoS One. 9(5), e98081 (2014).
pubmed: 24858067
pmcid: 4032235
doi: 10.1371/journal.pone.0098081
Gong, W. Y. et al. High serum IgA/C3 ratio better predicts a diagnosis of IgA nephropathy among primary glomerular nephropathy patients with proteinuria ≤ 1 g/d: An observational cross-sectional study. BMC Nephrol. 20(1), 150 (2019).
pubmed: 31039758
pmcid: 6492345
doi: 10.1186/s12882-019-1331-0
Zhang, J. et al. Serum immunoglobulin A/C3 ratio predicts progression of immunoglobulin A nephropathy. Nephrology (Carlton). 18(2), 125–131 (2013).
pubmed: 23134230
doi: 10.1111/nep.12010
Komatsu, H. et al. Relationship between serum IgA/C3 ratio and progression of IgA nephropathy. Intern Med. 43(11), 1023–1028 (2004).
pubmed: 15609695
doi: 10.2169/internalmedicine.43.1023
Stefan, G. et al. Is there a role for IgA/C3 ratio in IgA nephropathy prognosis? An outcome analysis on an European population. Iran J. Kidney Dis. 14(6), 470–477 (2020).
pubmed: 33277451
Chen, P. et al. Plasma galactose-deficient IgA1 and C3 and CKD progression in IgA nephropathy. Clin. J. Am. Soc. Nephrol. 14(10), 1458–1465 (2019).
pubmed: 31511226
pmcid: 6777583
doi: 10.2215/CJN.13711118
Zhu, B. et al. Clinical characteristics of IgA nephropathy associated with low complement 4 levels. Ren Fail. 37(3), 424–432 (2015).
pubmed: 25539484
doi: 10.3109/0886022X.2014.994408
Xiong, L., Liu, L., Tao, Y. & Guo, H. Clinical significance of IgM and C3 deposition in children with primary immunoglobulin A nephropathy. J. Nephrol. https://doi.org/10.1007/s40620-023-01724-7 (2023).
doi: 10.1007/s40620-023-01724-7
pubmed: 37542609
Iatropoulos, P. et al. Cluster analysis identifies distinct pathogenetic patterns in C3 glomerulopathies/immune complex-mediated membranoproliferative GN. J. Am. Soc. Nephrol. 29(1), 283–294 (2018).
pubmed: 29030465
doi: 10.1681/ASN.2017030258